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Abstract 
 
Maladaptive response control is a feature of many neuropsychiatric conditions, 
including Attention Deficit Hyperactivity Disorder (ADHD). As ADHD is more 
commonly diagnosed in males than females, a pathogenic role for sex-linked genes 
has been suggested. Deletion or point mutation of the X-linked STS gene, encoding 
the enzyme steroid sulfatase influences risk for ADHD. We examined whether 
deletion of the Sts gene in the 39,XY*O mouse model, or pharmacological 
manipulation of the steroid sulfatase axis, via administration of the enzyme substrate 
dehydroepiandrosterone sulfate or the enzyme inhibitor COUMATE, influenced 
behavior in a novel murine analogue of the stop-signal reaction time task used to 
detect inhibitory deficits in individuals with ADHD. Unexpectedly, both the genetic 
and pharmacological treatments resulted in enhanced response control, manifest as 
highly specific effects in the ability to cancel a pre-potent action. For all three 
manipulations, the effect size was comparable to that seen with the commonly used 
ADHD therapeutics methylphenidate and atomoxetine. Hence, converging genetic 
and pharmacological evidence indicate that the steroid sulfatase axis is involved in 
inhibitory processes and can be manipulated to give rise to improvements in response 
control. Whilst the precise neurobiological mechanism(s) underlying the effects 
remain to be established, there is the potential for exploiting this pathway in the 
treatment of disorders where failures in behavioral inhibition are prominent.     
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 3 of 37 
 
Introduction 
 
Deficits in impulse control are seen in many psychiatric illnesses, ranging from 
substance abuse, to pathological gambling, to neurodegenerative conditions (Brewer 
and Potenza, 2008). Maladaptive responding is also a prominent, though non-specific, 
feature of Attention Deficit Hyperactivity Disorder (ADHD), a neurodevelopmental 
condition that affects up to 6% of the population and that can have significant long-
term adverse consequences (Brewer and Potenza, 2008; Thapar et al., 2005). Aberrant 
response inhibition in ADHD has consistently been demonstrated in the stop-signal 
reaction time task (SSRTT), an assay of the ability to cancel an ongoing motor action 
in response to a ‘stop-signal’ (Crosbie et al., 2008). 
ADHD is more frequently diagnosed in males than in females (Holden, 2005), 
suggesting potential contributory sex-linked genetic mechanisms. Cytogenetic 
deletions encompassing the X-linked steroid sulfatase (STS) gene, or inactivating 
point mutations within it, result in an elevated rate of ADHD in comparison to the 
general population (Kent et al., 2008), and there is some evidence that polymorphisms 
within STS may influence ADHD risk and symptoms (Brookes et al., 2010; Brookes 
et al., 2008; Stergiakouli et al., 2011). The STS enzyme cleaves sulfate groups from a 
variety of steroids (notably dehydroepiandrosterone sulfate, DHEAS) and the 
substrates and products of the enzyme, and their multiple downstream effectors, can 
influence diverse neurobiological processes, via effects on the biosynthesis of 
androgens and oestrogens and on key neurotransmitter signalling systems (Reed et al., 
2005). Furthermore, STS is expressed in regions of the developing and mature human 
brain known to be important in impulse control, and whose structure/function is 
frequently perturbed in cases of ADHD, notably frontal cortex, basal ganglia and 
thalamus (Hart et al., 2013; Perumal et al., 1973; Stergiakouli et al., 2011).    
Here, we exploited our recent development of a murine analogue of the human 
SSRTT (Humby et al., 2013) to investigate the effects of manipulating the STS axis 
on response control in mouse models. To assess the effects of gene deletion we used 
the   39,XY*O mouse, in which the pseudoautosomal Sts and Asmt genes (encoding 
steroid sulfatase and acetylserotonin O-methyltransferase respectively) are deleted as 
consequence of an end-to-end fusion of the X and Y chromosomes (Trent et al., 
2013). We have shown that 39,XY*O mice exhibit diverse behavioral and endocrine 
phenotypes, including deficits in stimulus detection in the 5-choice serial reaction 
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time task consistent with impaired functioning in divided attention (Davies et al., 
2009), hyperactivity, heightened emotional reactivity, aggression (Trent et al., 2012b), 
increased perseveration (Trent et al., 2013; Trent et al., 2012a) and reduced DHEA 
levels (Trent et al., 2013; Trent et al., 2012b); we have suggested these findings 
overlap with some of the symptoms seen in ADHD. Here, we augmented the genetic 
approach with acute pharmacological manipulations involving systemic 
administrations of the STS substrate DHEAS and the enzyme inhibitor COUMATE 
(Reed et al., 2005). These additional manipulations were undertaken to confirm that 
any behavioral effects in the 39,XY*O mouse were due to loss-of-function of STS 
(rather than loss-of-function of ASMT) and to determine whether the STS-dependent 
effects were likely to be due to the enzyme’s developmental role alone, or to its 
ongoing activity into adulthood. Our initial prediction, based on the existing human 
literature linking STS to ADHD risk, was that steroid sulfatase loss or inhibition 
would result in impaired response control.    
We report that, in contrast to this prediction, both the genetic and 
pharmacological manipulations of STS function led to markedly enhanced response 
control in the SSRTT, and that these effects were comparable in magnitude and 
specificity to those seen with the commonly used ADHD therapeutics 
methylphenidate and atomoxetine. Whilst the neurobiological mechanism(s) 
mediating these effects remain to be established there is the potential for exploiting 
this pathway as an alternative to current therapies used to treat disorders where 
failures in behavioral inhibition are prominent. 
 
Materials and Methods     
 
Subjects 
 
Wildtype 40,XY MF1 mice (Harlan, UK, aged 3-4 months at start of testing) were 
used in initial work validating the SSRTT; this was necessary as our previous work 
used C57BL/6 strain mice (Humby et al., 2013). This group of mice were also used 
for the drug studies. For the genetic study, 39,XY*O and 40,XY mice on a 
predominantly MF1 background were bred, genotyped and treated prior to behavioral 
analysis as described previously (Trent et al., 2012a); subjects were aged 8-10 months 
at start of testing in the SSRTT. 39,XY*O mice were generated from two 
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karyotypically-distinct mothers (39,XPafO or 40,In(X)Paf/X), and several of the 
39,XY*O mice had to be housed individually due to their propensity to fight. 
Therefore, we explicitly tested post hoc for any effects of birth mother, or of single 
housing, on 39,XY*O behavior. Additionally, given that mice for the task 
specification/drug studies and the genetic studies differed in age, we also considered 
whether there might be potential confounds in the data due to ageing effects. All mice 
were housed in the same vivarium maintained at 21±2°C and 50±10% humidity, with 
a 12 hour light-dark cycle (lights on at 07:00hr), with food and water available ad 
libitum, unless stated otherwise. Animals were treated in accordance with the Animal 
(Scientific Procedures) Act (United Kingdom, 1986). 
 
SSRTT; habituation and training 
 
Reinforcer habituation, training and assessment of SSRTT task performance were as 
described previously (Humby et al., 2013 and Supplementary Materials and 
Methods).  Briefly, the animals were habituated to liquid reinforcer (10% condensed 
milk, Nestle Ltd) before undergoing SSRTT training in mouse 9-hole boxes 
(Campden Cognition, U.K). Training to baseline involved shaping the mice to 
respond sequentially at two stimulus locations, using nose-pokes, to give rise to a ‘go’ 
response, and then learning to withhold responding to the second stimulus location 
when an auditory stop-signal was presented, to give rise to a ‘stop’ response (Figure 
1a).  
 
SSRTT: behavioral manipulations 
 
Mice could perform a maximum of 100 trials (≤20min session duration), where 80% 
of trials were ‘go’ trials and 20% were interpolated ‘stop’ trials. At baseline, on ‘stop’ 
trials, the stop-signal was always presented coincident with the beginning of the 
response (i.e. 0% of the individual correct go reaction time for each subject), making 
stopping relatively easy, but in separate probe sessions the position of the stop-signal 
was varied relative to the individual correct go reaction times for each mouse making 
stopping more or less difficult i.e. at 10, 20, 30, 40, 50, 60, 70, 80 and 90% into the 
individualised go reaction time for each mouse (Figure 1a). At 90%, the stop signal 
was played close to the execution of the response, and hence stopping was most 
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difficult (Humby et al., 2013; Carter et al., 2003). There were at least three days at 
baseline criteria between each probe session, and the order of presentation of these 
sessions was randomised between subjects. 
 
SSRTT: pharmacological manipulations 
 
As previously (Humby et al., 2013), drug effects in MF1 mice were determined in 
sessions with a 50% stop-signal position, when subjects showed ~50% correct 
stopping. At this point, behavior conforms to the prevailing ‘race’ model of response 
inhibition, whereby the ability to cancel an ongoing motor action is dependent on 
competition between dissociable, parallel brain processes of going and stopping 
(Eagle and Robbins, 2003; Logan, 1994). Methylphenidate HCl (n=12, at doses of 0, 
0.3, 1, 1.5, and 3mg/kg, Sigma, U.K.) and atomoxetine HCl (n=12, at doses of 0, 0.6, 
1, 3 and 5mg/kg, Sigma, U.K.), at doses shown previously to be effective at 
modifying rodent SSRTT behavior (Humby et al., 2013; Robinson et al., 2008a; Eagle 
et al., 2007), were made up in physiological saline and administered 30mins prior to 
testing (i.p.). COUMATE was administered at 10mg/kg p.o. 24hrs before testing in 
0.5% methylcellulose physiological saline vehicle (n=11), and DHEAS (Sigma, UK) 
was administered at 40 mg/kg i.p. in distilled water vehicle one hour before testing, 
i.p. (n=12). The doses of COUMATE and DHEAS used had previously been shown 
to specifically affect aspects of cognition in similar operant tasks in mice (Davies et 
al., 2009). Drugs were given in a Latin square design, where animals were given a 
single session with each dose of drug and vehicle, with at least four days of stable 
performance at baseline criteria between each drug treatment to allow for washout.  
 
SSRTT: measures and statistical analyses 
 
Key measures from the SSRTT were % correct stop trials, stop-signal reaction time 
(SSRT), % correct go trials and correct go reaction time. Ancillary measures of 
general task performance included overall number of trials initiated, latency to initiate 
a trial and latency to enter the food magazine following a successful go or stop trial. 
For a full listing of measures and definitions see Supplementary Materials and 
Methods. SSRTs in the task were estimated employing the standard procedure 
described in Logan et al., (1984), using data from where the proportion of correct stop 
Page 7 of 37 
 
responses is ~50%. For each subject, data from the sessions in which the stop-signal 
positions were varied relative to the individualised go reaction time, were ranked by 
the proportion of correct stop responses, and data from sessions in which this value 
was between 40% and 60% (i.e. 50%±10%) were averaged. The latency of stopping 
as defined by the SSRT was derived from the distribution of correct go reaction times 
and the proportion of correctly stopped trials as previously described (Eagle and 
Robbins, 2003; Logan, 1994). Hence, for each of the sessions determined above, the 
correct go reaction times were rank ordered from smallest to largest and the nth value 
found, where n is the rank order position based on the proportion of failing to stop 
correctly in stop trials, corrected for the occurrence of omitted go trials (Eagle and 
Robbins, 2003; Solanto et al., 2001; Tannock et al., 1989). To determine the SSRT, 
the time the stop-signal was presented (i.e. ‘mean correct go reaction time’ x ‘% mean 
stop-signal position’) was subtracted from the nth correct go reaction time value 
(Supplementary Materials and Methods).  
Data were analysed using SPSS (V.18, SPSS Inc, U.S.A), and were subject to 
t-test or ANOVA. Between-group factors included GENOTYPE (40,XY vs. 39,XY*O) 
and DOSE (vehicle and dose of each drug), and within-group factors included STOP-
SIGNAL POSITION (0% (baseline)-90%) and STOP-PERFORMANCE (baseline 
responding vs. 50% correct stopping). Scores calculated as percentages were arcsine 
transformed prior to analysis. Where sphericity assumptions were violated, 
Greenhouse-Geisser corrections were used. If ANOVA indicated a significant 
interaction between factors, post hoc pairwise comparisons were performed using 
Tukey's Honestly Significant Difference test. Criterion level of significance was set at 
the 0.05 level, and all data are shown as mean ±standard error of the mean (S.E.M.) 
 
Results 
 
Behavioral specification of the SSRTT in adult male MF1 mice 
  
The MF1 mice were able to learn and perform the task to the same high degree of 
performance seen previously in C57BL/6 strain mice (Humby et al., 2013). On 
average, it took ~34 sessions to achieve stable baseline performance (defined as >70% 
initiated trials, >80% correct go responses and >80% correct stopping performance). 
At baseline, where the presentation of the auditory stop-signal occurred at start of the 
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go response, mice demonstrated high levels of stimulus control with rapid (2.7±0.1s) 
and high (74.4±3.1%) levels of responding to the initiating stimulus, go latencies 
comparable to those reported for rat and human subjects (731±29ms)(DeVito et al., 
2009; Eagle and Robbins, 2003), and high levels of successful stopping during stop 
trials (86.4±3.1%) and general motivation, as indexed by the rapid collection of 
reward following a successful trial (1.4±0.1s) (Table S1).   
The effects of altering the position of the auditory stop-signal during stop trials 
are illustrated in Figure 1b-h. Making stopping more difficult had the predicted effect 
on the ability of the mice to withhold responding, decreasing the proportion of 
correctly stopped trials (Figure 1b, effect of STOP-SIGNAL POSITION, 
F9,117=11.14, p=0.0001), but importantly not affecting correct go responding (Figure 
1c, effect of STOP-SIGNAL POSITION, F9,117=1.56, p=0.14) or go latencies in the 
interpolated go trials (Figure 1d, effect of STOP-SIGNAL POSITION, F9,117=1.48, 
p=0.17).  The mean position of the stop-signal that resulted in 50% correct stopping 
was 48.19±5.6% into the mean go responses times for these mice; at this point, mean 
SSRT was 319±28ms (Figure 1e), similar to that reported in human and rat tasks and 
C57BL/6 mice (Humby et al., 2013; Eagle et al., 2007; Tannock et al., 1989). There 
were modest, but significant, STOP-PERFORMANCE effects in some of the ancillary 
task measures, such as decreased proportion of trials initiated at 50% correct 
responding (Figure 1f, t13=3.92, p=0.002) together with increased latencies to initiate 
a trial (Figure 1g, t13=-2.48, p=0.027) and collect the reinforcer (Figure 1h, t13=-2.45, 
p=0.029).   
 
Effects of the clinically effective drugs methylphenidate and atomoxetine on SSRTT 
performance in adult male MF1 mice 
 
Consistent with our previous work in C57BL/6 mice (Humby et al., 2013), and that of 
others in rats (Robinson et al., 2008a; Eagle et al., 2007), the clinically effective drugs 
methylphenidate and atomoxetine enhanced stopping ability (Figure 2). There was a 
significant effect of methylphenidate administration on successful stopping (Figure 
2a, effect of DOSE, F4,44=2.67, p=0.04) and SSRT (Figure 2b, effect of DOSE, 
F4,44=11.09, p=0.001), consistent with quicker and more effective stopping.  Drug 
effects on stopping were highly specific with no effects on correct go responding 
(Figure 2c, effect of DOSE F4,44=0.97, p=0.43) or go latency (Figure 2d, effect of 
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DOSE, F4,44=1.06, p=0.39). Moreover, there were no significant effects of 
methylphenidate on other general features of SSRTT behavior (Figure S2). 
Administration of atomoxetine also increased successful stopping (Figure 2e, effect 
of DOSE, F4,44=7.46, p=0.001) and decreased SSRT, relative to vehicle treatment 
(Figure 2f, effect of DOSE, F4,44=4.11, p=0.01). Atomoxetine administration did not 
affect the go response (Figure 2g-h, effect of DOSE, F4,44=1.67, p=0.18 and 
F4,44=0.90, p=0.47, for correct go responding and go latency, respectively); 
atomoxetine administration at all doses tended to reduce the proportion of trials 
initiated, there were no significant effects on ancillary measures (Figure S2).  
 
Enhanced response inhibition in 39,XY*O mice relative to 40,XY mice 
 
39,XY*O mice were equivalent to 40,XY controls in terms of reinforcer preference, 
and progression through the training stages of the SSRTT, reaching stable baseline 
performance in ~39 sessions (Table S2). Both groups of mice showed high levels of 
stimulus control at baseline, initiating >70% of trials, achieving >80% go and stop 
responses with rapid go reaction times (~700 ms); both groups also showed efficient 
patterns of behavior in relation to nose-poke responses/trial initiation (40,XY: 
1.12±0.02 vs. 39,XY*O: 1.15±0.02) and the rapid collection of reward following a 
successful trial (40,XY: 1.98±0.36s vs. 39,XY*O: 1.88±0.33s) (Table S2). 
Altering the position of the auditory stop-signal during stop trials, by 
presenting the auditory stop stimulus progressively closer to the execution of the go 
response, led to systematic reductions in the ability to stop for both groups of mice 
(Figure 3a, effect of STOP-SIGNAL POSITION, F9,225=25.46, p=0.001). However, 
39,XY*O mice were less affected by this task manipulation (interaction of 
GENOTYPE x STOP-SIGNAL POSITION, F9,225=3.32, p=0.001), confirmed by 
pairwise comparisons showing that successful stopping was significantly different 
between 40,XY and 39,XY*O mice (p<0.05) when the stop-signal was presented at 
30-70% positions, but not at baseline (0%), 10%, 20%, 80% or 90% stop-signal 
positions. In contrast, there were no significant between group differences in correct 
go responses (Figure 3b, effect of GENOTYPE, F1,25=1.48, p=0.24) or in correct go 
reaction times (Figure 3c, effect of GENOTYPE, F1,25=2. 39, p=0.13).  
Calculation of the SSRT at the 50% correct stopping point showed that 
39,XY*O mice had significantly quicker stop latencies than 40,XY mice (Figure 3d,  
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t25=3.24, p=0.01). Together with the increased proportion of correctly stopped trials, 
these data indicated more rapid and effective stopping in the 39,XY*O mice. 39,XY*O 
mice initiated more trials than 40,XY mice at baseline and when they were at the 50% 
correct stopping point (Figure 3e, effect of GENOTYPE, F1,25=12.62, p=0.002), but 
were not quicker to start a trial (Figure 3f, effect of GENOTYPE, F1,25=3.98, p=0.06), 
or to collect the reinforcer (Figure 3g, effect of GENOTYPE, F1,25=2.31, p=0.14). 
There were no differences in these measures at baseline or 50% correct stopping 
performance (effect of STOP-SIGNAL POSITION, F1,25=0.56, p=0.46, F1,25=2.29, 
p=0.14, F1,25=0.93, p=0.35 for the proportion of initiated trials, latency to initiate a 
trial and latency to collect the reinforcer, respectively). The clear dissociations 
between 39,XY*O effects on stopping and going behaviors made it unlikely that the 
enhanced stopping in 39,XY*O mice was due to adoption of some qualitatively 
distinct behavioral strategy (e.g. postural), but to be sure, the lack of any such 
difference was confirmed by video analysis. 39,XY*O mice were generated from two 
karyotypically-distinct mothers, and some of these mice had to be individually housed 
during testing. The data were indifferent to either of these potentially confounding 
factors, insofar as the key SSRTT measures did not differ between 39,XY*O mice 
from the two types of mother (Table S3), nor between singly- and group-housed 
39,XY*O mice (Table S4). 
 
Pharmacological manipulation of Sts function also enhances response inhibition in 
adult male MF1 mice 
 
Treatment with both the enzyme inhibitor COUMATE (Figure 4) and its substrate 
DHEAS (Figure 5) enhanced inhibition, as evidenced by significant DOSE effects on 
successful stopping (Figure 4a, t10=-4.53, p=0.001; Figure 5a, t11=-5.59, p=0.0001, 
respectively) and more rapid SSRTs (Figure 4b, t10=3.10, p=0.011; Figure 5b, 
t11=2.44, p=0.03, respectively). In the case of COUMATE the effects on stopping 
were not accompanied by changes in going behaviors (Figure 4c, t10=-1.89, p=0.20 
for correct go responding and Figure 4d, t10=-0.24. p=0.81, for the go latency) or on 
other general features of behavior, such as the overall trials initiated (Figure 4e, t10=-
0.22, p=0.83), trial initiation latency (Figure 4f, t10=1.01, p=0.33) or the reinforcer 
collection latency (Figure 4g, t10=-2.21, p=0.06). As with COUMATE there were no 
effects of DHEAS on correct go responding (Figure 5c, t11=0.22, p=0.83), the latency 
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in go trials (Figure 5d, t11=-1.13. p=0.28) or trial initiation latency (Figure 5f, 
t11=2.09, p=0.06); however, there was a significant reduction in the number of trials 
initiated (Figure 5e, t11=5.41, p=0.0001) and an increase in the reinforcer collection 
latency (Figure 5g, t11=-3.23, p=0.008). 
 
Discussion 
 
We report novel effects of manipulating the steroid sulfatase axis on response control 
assayed in a recently developed murine analogue of the SSRTT which permits a high 
degree of translation between human clinical populations and rodent models (Humby 
et al., 2013; Humby and Wilkinson, 2011). The MF1 outbred mice used in the present 
studies were able to learn and perform the SSRTT, exhibiting high levels of stimulus 
control. Furthermore, as in people, performance was dissociable in terms of going and 
stopping, and was therefore consistent with the prevailing ‘race’ model of behavioral 
inhibition whereby action cancelation is dependent on competition between discrete 
brain processes of going and stopping (Logan, 1994). Additionally, stopping abilities 
were enhanced following systemic administration of the mixed 
dopamine/noradrenaline reuptake inhibitor methylphenidate and the more specific 
noradrenaline reuptake inhibitor atomoxetine, recapitulating the effectiveness of these 
drugs on response control in clinical and healthy human populations (De Vito et al., 
2009; Chamberlain et al., 2006; Aron et al., 2003; Tannock et al., 1989).  
A main finding of the current work was the inhibition-promoting effects of the 
genetic mutation in the 39,XY*O mice. This was not predicted on the basis of the 
existing ADHD/STS clinical literature but was consistent, in part, with previous data 
showing reduced premature responding in these same mutants in the 5-choice serial 
reaction time task (Davies et al., 2009). Importantly, the present findings were highly 
specific, and in particular unlikely to be confounded by the increased activity and 
‘response rate’ phenotypes previously reported in 39,XY*O mice (Trent et al., 2013; 
Trent et al., 2012b) in that these phenotypes might be anticipated to be associated 
with greater difficulty in stopping. Moreover, go response latencies, which were likely 
to have been affected by between-group differences in non-specific factors such as 
activity, were equivalent across 40,XY and 39,XY*O genotypes.  
We sought confirmation of the genetic finding by testing the effects of acute 
enzyme inhibition using COUMATE at a dose previously shown to inhibit brain 
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activity in mice by ~70% but to have no effect on locomotor activity (Davies et al., 
2009; Nicolas et al., 2001). This experiment was an important control to confirm that 
the phenotype in the 39,XY*O mice was due solely to steroid sulfatase deficiency 
(rather than lack of acetylserotonin O-methyltransferase; the other gene deleted in 
39,XY*O mice (Trent et al., 2013)) and also allowed us to distinguish whether the 
behavioral effects arose due to the developmental and/or ongoing effects of enzyme 
deficiency. We found that acute administration of COUMATE had the same highly 
specific effects as the constitutive genetic lesion in the 39,XY*O mice (i.e. enhancing 
stopping abilities in the absence of effects on going behaviors) consistent with an 
effect of acute regulation of steroid sulfatase on response inhibition in adult brain. The 
converging evidence from genetic and pharmacological approaches argued strongly 
against the possibility that the 39,XY*O data were confounded in some way by the 
mother’s karyotype or by the requirements for single housing in some cases. 
Similarly, the convergent data across the group of younger adult mice used for the 
task specification/pharmacological studies and older adult mice used for the genetic 
studies, together with the general similarity in behavioral performance across the 
groups, indicated the data were not confounded by age effects.   
We further probed the effects of acute manipulation of the steroid sulfatase 
axis by administration of the enzyme substrate DHEAS at a dose reported to have no 
effects on locomotor activity (Davies et al., 2009). Again, this treatment led to 
enhanced stopping performance without influencing going trials or most general 
aspects of behavior (although the drug did reduce overall number of trials initiated).  
Administration of DHEAS at the same dose and route used in the present work, 
results in elevated brain levels of both DHEAS and DHEA (the direct product of STS 
action on DHEAS) within one hour in male mice (Nicolas and Fry, 2007). Therefore, 
the DHEAS effects on stopping we observed could have been the result of increased 
levels of DHEAS and/or DHEA in the brain. However, given that the effects of 
DHEAS administration on stopping resemble those elicited by enzyme inhibition and 
Sts gene deletion, and the latter two manipulations impair the conversion of DHEAS 
to DHEA (Trent et al., 2013; Nicolas and Fry, 2007; Rhodes et al., 1997), the 
common causal factor in enhancing control of responding in the SSRTT across the 
three experimental procedures was most likely to have been increased DHEAS levels. 
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Our current and previous data using animal models reveal a consistent pattern 
of effects, whereby impaired, or absent, STS function leads to both enhanced response 
control and attentional deficits (Davies et al., 2009; Davies et al., 2007). In rodents 
attentional and impulsivity phenotypes are dissociable both psychologically and in 
terms of discrete underlying neural substrates (Bari and Robbins, 2013; Robbins, 
2002), and work by Blondeau and Dellu-Hagedorn (2007) has shown individual 
differences whereby the same animal can display inattention with relatively high 
levels of response control. However, the precise neurobiological basis of the 
dissociable effects of STS manipulations on attention and response control remains to 
be established. In the rat 5-choice serial reaction time task, lesions of the nucleus 
basalis magnocellularis (Risbrough et al., 2002) and the pedunculopontine tegmental 
nucleus (PPTg)(Inglis et al., 2001) have been reported to result in impaired attention 
and reduced impulsivity, though to our knowledge the effects of equivalent lesions on 
stop-signal performance have not yet been reported. In rodents, the basal forebrain 
cholinergic complex projects directly to the cortex, thalamus and hippocampus, whilst 
the pontine cholinergic system projects to the thalamus and basal forebrain, and to a 
lesser extent to the cortex (McKinney et al., 2005). Given that Sts is highly expressed 
in the mammalian thalamus and cortex (Stergiakouli et al., 2011; Compagnone et al., 
1997; Perumal et al., 1973) i.e. key neural substrates in attention and impulsivity 
(Bonelli and Cummings, 2007; Robbins, 2007), and that both acute DHEAS 
administration (Rhodes et al., 1996) and STS inhibition (Rhodes et al., 1997) have 
been shown to influence acetylcholine release, we speculate that steroid sulfatase 
deficiency may give rise to the observed dissociable pattern of behavioral effects 
through affecting the integrity or function of cholinergic projections from the basal 
forebrain and/or the PPTg to the thalamus and cortex.  
Additionally, or alternatively, steroid sulfatase deficiency could affect 
attention and impulsivity through effects on monoaminergic function, including 
serotonergic function (Trent et al., 2013; Trent et al., 2012a) which is increasingly 
being recognised as an important modulator of inhibitory control (Dalley and Roiser, 
2012); interactions between the serotonergic and cholinergic systems, notably within 
the basal forebrain, are known to be important in mediating cognition (Steckler and 
Saghal, 1995). STS is expressed in the developing and adult striatum (Stergiakouli et 
al., 2011; Compagnone et al., 1997; Perumal et al., 1973) and, behaviorally, the 
effects of manipulating the steroid sulfatase axis on response control appeared to be 
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similar in magnitude and pattern to the effects of methylphenidate and atomoxetine; 
hence, it is also possible that steroid deficiency exerts its inhibitory effects in the stop-
signal task in a manner analogous to these drugs i.e. through influencing synaptic 
levels of dopamine and/or noradrenaline in the fronto-striatal regions (Bari and 
Robbins, 2013). To date, there is no published evidence that steroid sulfatase 
deficiency influences synaptic levels of these monoamines, although in 39,XY*O mice 
there is a trend towards increased striatal tissue dopamine concentrations (Trent et al., 
2012a). Additionally, there is increasing evidence for dissociations within, and 
between, processes of attention and response control mediated by differential effects 
of monoaminergic transmission occurring in distinct regions of the fronto-striatal 
circuitry (e.g. Economidou et al., 2012; Pezze et al., 2007; Robinson et al., 2008b; 
Winstanley et al., 2003). However, predictions as to how STS may impact on 
attention and response control differentially via such brain area-specific 
monoaminergic mechanisms are hindered by a current lack of knowledge about the 
functions of the enzyme in discrete components of the fronto-striatal circuitry.  
The steroid sulfatase axis, including the direct substrates and products of the 
enzyme and their downstream effectors, could also in theory be influencing inhibitory 
and attentional  processes in brain via multiple other routes, including via effects on 
gamma-aminobutyric acid receptor A (GABAA) function, N-methyl-D-aspartate 
(NMDA) receptor function or sigma 1 receptor function (Davies, 2012; Reed et al., 
2005). Future work examining the behavioral effects of agonists and antagonists at 
these receptors in 39,XY*O and COUMATE-treated mice will allow us to determine 
which, if any, of these pathways are mediating the observed STS-dependent effects.  
ADHD is a condition underpinned by complex genetic aetiology presenting 
with mixtures of hyperactivity, inattention and impulsive responding. Sub-groups of 
individuals with the disorder may be differentiated based upon their cognitive profile 
(Sonuga-Barke et al., 2008). Importantly in the context of the present findings, no 
clear mediating role of aberrant inhibition in ADHD has yet been demonstrated; 
indeed, defective information processing, associated with a more cautious response 
style in some cognitive tasks, has recently been proposed as the key specific 
mechanism underlying ADHD pathophysiology (Salum et al., 2013). Clearly any one 
animal model, including those described here, cannot recapitulate the whole of the 
ADHD spectrum of symptoms, at least in any simple way. However, consistent with 
our animal data, cytogenetic deletions that include the STS gene (or inactivating point 
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mutations within the gene) are associated with increased risk of developing inattentive 
subtype ADHD (Kent et al., 2008) whilst  polymorphisms within STS are specifically 
associated with inattentive symptoms rather than impulsive or hyperactive symptoms 
(Stergiakouli et al., 2011; Brookes et al., 2008). Whether steroid sulfatase-deficient 
individuals exhibit enhanced response inhibition as we might predict from our present 
data, and whether these subjects exhibit neural abnormalities in the pathways 
mentioned above remains to be investigated. Similarly, the extent to which response 
control is altered in individuals treated with steroid sulfatase inhibitors as a therapy 
for hormone-dependent cancers (Purohit and Foster, 2012), or in healthy and clinical 
populations administered DHEA(S) (e.g. Ritsner, 2011; Maninger et al., 2009; 
Grimley Evans et al., 2006) has not yet been explicitly assessed. Overall, our findings 
suggest that steroid sulfatase deficiency, or pathologies giving rise to analogous 
neural abnormalities, may contribute towards the pathophysiology of ADHD cases 
characterised by inattention with normal (or enhanced) response inhibition. 
In conclusion, converging genetic and pharmacological evidence indicate that 
the steroid sulfatase axis is involved in inhibitory processes and can be manipulated to 
give rise to highly specific and substantial improvements in response control. 
Additional work specifying neurobiological changes elicited by steroid sulfatase 
deficiency (e.g. Trent et al., 2014) is needed to fully understand the mechanism(s) of 
action by which such manipulations impact upon dissociable components of attention 
and response control. We suggest the steroid sulfate axis, or more likely its 
downstream effectors acting on inhibitory processes, might represent viable 
therapeutic targets for the treatment of ADHD and other disorders where failures in 
behavioral inhibition are prominent. 
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Figure Legends 
 
Figure 1. The Stop-Signal Reaction Time Task (SSRTT), baseline and task 
manipulations in adult MF1 40,XY mice (n=14). The SSRTT consisted of two 
interpolated trial types: Go trials (80%), and Stop trials (20%). Subjects initiated a go 
trial by a nosepoke response to a stimulus in the left-hand hole (ai); this resulted in the 
go stimulus (light in right-hand hole) being illuminated (aii). A correct nosepoke 
response at the go stimulus resulted in the delivery of reinforce (aiii). Stop trials were 
also initiated by a left nosepoke (aiv), which subsequently resulted in presentation of 
a light in the right-hand hole (av). However, on these trials an auditory stop signal 
was presented after trial initiation, instructing the mouse to inhibit responding to the 
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second stimulus (av). Successful stopping resulted in reinforce presentation on these 
trials (avi). The stop signal was presented at increasing intervals into a mouse’s 
individualised reaction time, with early stop signals (0%) allowing for easier stopping, 
and later signals, close to the execution of the second stimulus response (90%), 
making stopping more difficult. Assessment of SSRTT performance in MF1 mice 
showed that presenting the auditory ‘stop-signal’ progressively closer to the end of the 
individual go response made stopping more difficult (b), but did not affect the 
proportion of correct go trials (c), or the speed of the go response (d). Further analysis 
of SSRTT performance was conducted to examine the point where competition 
between the go and stop responding was at its greatest; thus, data from each subject 
was ranked and sessions where correct stopping was at 50±10% averaged. At this 
point the SSRT, the latency to withhold responding, was calculated (e). When 
stopping with 50% accuracy, there were small but significant changes from baseline 
(BL) performance in other performance measures, such as a decrease in the 
proportion of trials initiated (f) and increases in the latency to initiate a trial (g) and 
the time taken to enter the food magazine following a successful trial (h). ** denotes 
p<0.01 for significant difference between test condition.   
 
Figure 2. Effects of methylphenidate and atomoxetine administration on stop-
signal reaction time task performance in adult MF1 40,XY mice (n=12). At all 
doses used, methylphenidate improved stopping performance (a) and reduced the 
SSRT (b), but did not affect the proportion of correct go trials (c) or the latency to 
make a correct go response (d). Administration of atomoxetine increased successful 
stopping (e) and decreased the SSRTT (f). The specificity of atomoxetine to affect 
stopping was shown by a lack of effects on the proportion of correct go trials (g) and 
speed of the go response (h). Baseline data (BL i.e. mean of the five sessions 
immediately preceding each drug treatment session) when the stop-signal presentation 
was concurrent with the start of the go response (0%) are shown for illustrative 
purposes and were not included in the statistical analysis.  
 
Figure 3. Comparison of stop-signal reaction time task performance in 39,XY*O 
(n=16)  and 40,XY (n=11) adult MF1 male mice. Altering the stop-signal position 
led to a systematic decrease in the ability of all the mice to stop, although 39,XY*O 
mice were less affected by this manipulation than 40,XY mice (a). The effects of the 
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genetic manipulation were highly specific, in that there were no between-group 
differences in the proportion of correct trials (b) or speed of correct responding (c).  
39,XY*O mice were quicker to stop than 40,XY control mice, reflected by a decrease 
in their SSRT (d). 39,XY*O mice initiated more trials than 40,XY mice, both at 
baseline and at 50% correct stopping (e). There were no significant group differences 
in the latencies to initiate a trial (f) or to collect the reinforcer (g). ***, ** and * 
denote p<0.001, p<0.01 and p<0.05, respectively for significant pairwise differences 
between groups. 
 
Figure 4. Effects of COUMATE administration (10mg/kg) on stop-signal 
reaction time task performance in adult male MF1 mice (n=11). COUMATE 
treatment increased the proportion of correctly stopped trials (a) and decreased the 
SSRT (b). Effects of COUMATE were specific to the stop response, as there were no 
effects on the proportion of correct go trials performed (c) or correct go reaction time 
(d); nor were there any group effects on the number (e) or latency (f) to initiate trials, 
or in the latency to collect reinforcer (g). Baseline data (BL i.e. mean of the five 
sessions immediately preceding each drug treatment session) when the stop-signal 
presentation was concurrent with the start of the go response (0%) are shown for 
illustrative purposes and were not included in the statistical analysis. *** and ** 
denote p<0.01 and p<0.001, respectively for significant pairwise differences between 
drug treatments. 
 
Figure 5. Effect of dehydroepiandrosterone sulfate (DHEAS) administration 
(40mg/kg) on stop-signal reaction time task performance in adult male MF1 mice 
(n=12). Administration of DHEAS increased the proportion of correctly stopped trials 
(a) and decreased SSRT (b).  Although there was no effect of drug treatment on the 
correct go response measure (c) or on the speed of the correct go response (d), 
DHEAS administration did result in effects on general task performance, such as 
reducing the number of trials initiated (e) and increasing reinforcer collection latency 
(g); there was also a near-significant increase in the latency to initiate trials (f).  
Baseline data (BL i.e. mean of the five sessions immediately preceding each drug 
treatment session) when the stop-signal presentation was concurrent with the start of 
the go response (0%) are shown for illustrative purposes and were not included in the 
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statistical analysis. *** and * denote p<0.001 and p<0.05, respectively for significant 
pairwise differences between drug treatments. 
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Supplementary Materials and Methods 
 
Apparatus 
 
The stop-signal reaction time task (SSRTT) was performed in mouse 9-hole chambers (Humby and 
Wilkinson, 2005; Humby et al., 1999)(Campden Cognition, U.K.) with the task under the control of custom 
written software. Each test chamber (14 x 13 cm) was enclosed in a sound attenuating box equipped with a 
fan to provide ventilation and also a consistent level of background noise.  The test chamber was equipped 
with 9 circular response apertures (10mm diameter) arranged in an arc on the back wall.  Each aperture was 
configured with a vertically orientated infra-red beam and a 40mA stimulus light at the distal end.  For the 
SSRTT the stimulus array was configured such that only two of the stimuli apertures were open (the others 
were blocked by black plastic).  The open apertures, holes number 3 and 7 (from the left), were equally 
placed relative to the centre line of the chamber and were designated as the initiation and go responses, 
respectively.  The near wall, including the access door, held the food magazine (2cm wide) which was 
enclosed by a clear Perspex door and could also be illuminated by a 60mA lamp. Openings of the food 
magazine door were recorded by the triggering of a micro-switch, as panel pushes. Reward was delivered 
into a small well in the floor of the food magazine via a 21 gauge hypodermic needle and 0.8mm silicone 
tubing from a peristaltic pump located outside of the test chamber but within the sound attenuating box.  A 
60mA house light and speaker were fitted to both side walls of the test chamber and a pair of infra-red 
beams which spanned the chambers, perpendicular to the stimulus array and 5 mm above the grid floor, 
were used to record motor activity. An infra-red camera (Watac, U.S.A.) mounted inside the sound 
attenuating box permitted observation and recording of behaving mice. The white noise stop-signal was 
provided by a custom built sound generator.   
 
Stop-signal reaction time task (SSRTT): initial shaping and training to baseline 
 
Training for the SSRTT followed the previously used methods (Humby et al., 2013).  Mice were handled for 
four weeks prior to the start of the study to habituate them to being picked up and moved. After this period, 
as above, they were placed on a regime of limited home cage water to motivate behavior in the task; this 
included a stepwise decrease in access time until water was available for 2 hours/day. Mice were maintained 
on this water restriction schedule on weekdays for the duration of behavioral testing, with ad libitum access 
to water at weekends. Task and drug manipulations were only undertaken after a successful day’s baseline 
performance under water restriction. The mice were then habituated to the reward (10% condensed milk 
solution (CMS), Nestle, U.K.) over a six day period (Humby and Wilkinson, 2005; Humby et al., 1999). 
Briefly, mice were individually placed into a test box (17cm wide x 49cm long x 14cm high) in which two 
small vessels were located near the far end, for a single 10 min session each day. On the first 2 days these 
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vessels both contained water and on the subsequent days on contained 10% CM (sides were alternated each 
day). The weights of each vessel before and after the session were recorded and the consumption of each 
calculated.  On the next day the mice were introduced into the test chambers and underwent training through 
an initial shaping stage followed by four main stages of training to SSRTT baseline. 
 
Initial shaping: Mice were always placed into the same test chamber at the same time of day throughout 
testing and all sessions were run with the house lights extinguished, unless illuminated during a time out 
period.  For the first six days of testing, where the aim was to habituate the mice to the test chambers and for 
them to learn where reinforcer would be delivered, all stimulus apertures were masked by black plastic 
covers. Thus, for the first 3 days of testing the doors to the food magazine were held open for the entire 
session (20mins) and reward (20µl of 10% CMS) was delivered every 30s. In the next three sessions the 
food magazine door had to be opened by the mice to gain access to the reward, and the number of door 
opening was recorded.   
 
Stage 1, single nose-poke training: In the next phase of training, the 3rd stimulus aperture, the left-hand 
location in the stimulus array, was uncovered and the mice were trained to make a nose poke to initiate the 
delivery of the reward (Figure S1). As previously, sessions were run in darkness for either 20min or 100 
completed trials.  A trial consisted of illumination of the stimulus in aperture 3 for 30s. On making a nose 
poke the stimulus was extinguished and reward was delivered. Exiting the food magazine triggered 
presentation of the next stimulus. If no nose poke was made the house light was illuminated for 5s (a time 
out) and the next trial initiated after this time. For every 5 consecutive correct trials 5s was deducted from 
the stimulus presentation time until a duration of 10s was reached, where the duration was fixed. After the 
first session where the stimulus was set at 30s, subsequent sessions started with a stimulus duration set at the 
final duration achieved in the previous session with the addition of 5s. Once mice had shown criteria 
performance (>70% correct trials with a starting stimulus duration of 10s) they were move to the stage of 
training. 
 
Stage 2, double nose-poke training (learning to go):In the second phase of formal training, the mice were 
trained to make a rapid transition between the two stimuli locations, thus aperture seven, the right-hand 
location in the stimulus array, was now uncovered (Figure S1). Trials now consisted of a 10s presentation of 
the initiation stimulus in aperture three, which, on completion of a nose poke response (the ‘initiation’ 
response), led to illumination of the stimulus in aperture seven (the ‘go’ response). Reinforcer was only 
presented on completion of both nose poke responses and missing either (i.e. not starting a trial or omitting 
the go response) led to a 5s time out period and the start on the next trial.  Consistent with the previous stage 
of training, the duration of the go stimulus (or go limited hold [LH]) was initially set to 30s and was reduced 
by 5s for every run of five consecutive correctly completed trials and new sessions began with the final 
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duration achieved in the previous session plus 5s. However, at this more advanced stage of training the aim 
was to get the mice responding rapidly, so the final go LH aimed at was one which was equivalent to the 
correct go reaction time (latency to make the go response) for each individual mouse.  Once this point had 
been achieved, and mice were showing >70% completed trials and >80% correct go responses, for three 
consecutive sessions they progressed to the next stage of training. 
 
Stage 3, learning to stop: In the penultimate stage of training, in 20% of trials a 0.3s 100db burst of white 
noise (the ‘stop-signal’) was presented coincident with the initiation nose-poke response (Figure S1). Thus, 
the auditory stop-signal was presented at the start of the go response. Initially, reward was delivered 0.35s 
from the onset of the white noise (the stop-signal LH), if the mouse has successfully withheld its go 
response.  Thus, initially mice did not have to wait to receive reward, however the stop LH period was 
gradually increased in 0.2s steps for every 5 consecutive correct stop trials completed, thus making the mice 
have to wait longer before they received reinforcer. Similar to the previous training stage, new sessions were 
started with a delay equivalent to the final one achieved in the previous sessions less 0.2s until the final 
delay reached was equivalent to the go stimulus duration with >80% correct stopping performance, >70% 
completed trials and >80% correct go responses (Figure S1).  
 
Stage 4, training to baseline: Both the go and stop limited hold values were fixed at the final values 
achieved through training, and which gave rise to stable criteria performance of >70% initiated trials, >80% 
correct go trials and >80% correct stop trials. In any given baseline session, 100 trials (or 20min) were 
available with 80% go trials and 20% interpolated stop trials. The auditory stop-signal was always presented 
at the start of the go response during baseline sessions, i.e. 0% position relative to the individualised correct 
go reaction times of each subject.   
 
Manipulations at performance: As detailed in the main Methods and Materials section of the main paper, at 
stable baseline performance a number of manipulations were assessed, including altering the position of the 
auditory stop-signal to make stopping more or less difficult (Carter et al., 2003; Eagle and Robbins, 2003; 
Logan, 1994) and monitoring the effects of drugs. At baseline, in stop trials the stop-signal was always 
presented coincident with the beginning of the response (making stopping relatively easy) but in separate 
probe sessions the position of the stop-signal was presented at different positions relative to the individual 
correct go reaction times of each mouse, i.e. at 0%, 10%, 50% and 90% into the individualised go reaction 
time, where 90% is close to the execution of the response and stopping therefore more difficult, as described 
in Logan (1994). Individualised reaction times were required to normalise the relative position of the stop-
signal across individuals, this was important since animals can have differing go reaction times. Individual 
correct go reaction times were monitored within-session and updated, thereby ensuring consistent placement 
of the stop-signal for each subject across all experimental conditions. Correct go reaction times were 
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determined directly, however the stop-signal reaction time (SSRT) had to be derived from the distribution of 
correct go reaction times and the proportion of correctly stopped trials. SSRTs were derived from data 
obtained from sessions with a 50% stop-signal position, when subjects showed ~50% correct stopping, in 
order to ensure balanced contributions from underlying psychological and brain processes of going and 
stopping according to the predominant ‘race’ model of behavioral inhibition as assayed in the SSRTT 
(Carter et al., 2003; Eagle and Robbins, 2003). Drug studies were also performed with sessions where the 
stop-signal was presented 50% into the individualised go reaction time of each subject. 
 
Figure S1 
 
 
 
Mouse SSRTT acquisition. Training to baseline involved shaping the mice to make nose-pokes at two locations in the stimulus 
array, an initiation response to the left and then a go response to the right-hand location, before then learning to withhold 
responding when an auditory stop-signal was presented.  Each new aspect of the procedure was added during separate stages of 
training.  Sessions were terminated after 100 trials had been presented or 20min had expired. Following initial shaping, in the 
first stage of training the mice were trained to make a single nose-poke to earn a reward, the ‘initiation response’, by gradually 
reducing the initiation stimulus duration from 30s to 10s.  Once criteria performance was achieved in Stage 1 (>70% trials 
completed) the mice were trained to make a rapid ‘go’ response between the two stimulus locations to earn reward (Stage 2). 
The go stimulus duration was initially set to 30s, and the duration was reduced to a value corresponding to the correct response 
latency for each individual subject, the go limited hold. Once at criteria performance (>80% correct going), a brief auditory 
stimulus was introduced in 20% of initiated trials (designated as ‘stop trials’) and the mice trained to withhold responding to the 
go response (Stage 3). The 0.3s long stop-signal was always presented at the start of the go response during training and 
baseline, i.e. 0% position relative to the individualised correct go reaction times of each subject. The duration that the mice 
were expected to wait for the reward delivery, the stop limited hold, was gradually increased to a value approximately 
equivalent to the go limited hold. Once the mice were at criteria stopping (>80% correctly stopped trials), the go and stop 
limited hold values were fixed (i.e. baseline performance) and the performance of each subject allowed to stabilise (Stage 4). 
Once the animals had demonstrated stable performance at criteria (>70% trials initiated, and >80% correct go and stop trials), 
task manipulations such as moving the presentation time of the stop-signal, and assessing the effects of drugs were assessed. 
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Supplementary Results 
 
Table S1: Stop-signal reaction time task acquisition in male MF1 mice (n=14) 
 1. Single nose-poking 2. Double nose-poking 3. Learning to stop 4. Training to BL 
 First session Last session First session Last session First session Last session First session Mean BL 
Number of sessions - 6.7±0.6 - 11.6±1.1 - 6.9±1.0 - 8.8±2.1 
Number of trials  38.2±5.6 98.9±0.8 78.4±3.8 94.4±3.9 97.0±2.4 99.1±0.5 90.6±3.1 99.5±0.3 
Trials initiated (%) 62.7±5.9 64.1±4.51 48.6±4.7 68.9±5.8 74.9±3.8 70.8±4.7 49.9±8.0 66.9±3.5 
Initiation latency (s) 18.6±2.3 3.2±0.1 3.9±0.2 3.1±0.2 2.9±0.2 2.8±0.2 3.7±0.3 2.9±0.2 
Initiation stimulus duration (s) 10 10 10 10 10 10 10 10 
Latency to collect reward (s) 5.9±2.4 3.9±1.9 2.4±0.2 1.5±0.1 2.2±0.7 1.4± 1.8±0.3 1.3±0.1 
Go correct trials (%) - - 73.8±3.7 79.1±2.7 80.6±4.1 82.7±3.3 67.4±9.1 85.6±2.5 
Go reaction time (ms) - - 6223.7±804.6 768.7±30.3 818.3±38.6 770.2±30.5 817.9±50.7 746.2±25.9 
Go Stimulus duration (s) - - 30.0±0.0 2.0±0.1 1.0±0.1 1.0±0.1 0.9±0.1 1.0±0.1 
Stop correct trials (%) - - - - 98.8±1.2 79.8±5.3 55.6±10.0 86.3±3.4 
Stop incorrect reaction time (ms) - - - - 510.0±0.0 666.6±30.5 643.8±21.8 602.1±13.7 
Stop signal position (%) - - - - 0 0 0 0 
Stop signal limited hold (s) - - - - 0.35±0.00 0.71±0.02 0.66±0.08 0.74±0.02 
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Figure S2. Effects of methylphenidate and atomoxetine on general aspects of SSRT performance in adult male MF1 mice (n=12) 
The specificity of methylphenidate effects to the stopping response was demonstrated by the lack of effects on the proportion of trials initiated (a, effect of 
DOSE, F4,44=1.77, p=0.15), latency to initiate a trial (b, effect of DOSE, F4,44=1.77, p=0.15) or the time taken to enter the food magazine to collect reinforcer 
following a successful stop or go trial (c, effect of DOSE, F4,44=0.16, p=0.96). Atomoxetine administration significantly reduced the number of trials initiated 
(d, effect of DOSE, F4,44=4.83, p=0.03), but did not affect the latency to initiate new trials (e, effect of DOSE, F4,44=1.11, p=0.36) or the latency to collect the 
reinforcer (f, effect of DOSE, F4,44=1.86, p=0.13). Baseline data (BL, the mean of the five sessions immediately preceding each drug treatment session) when 
the stop-signal presentation was concurrent with the start of the go response (i.e. at 0%) are shown for illustrative purposes and were not included in the 
statistical analysis.  
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Table S2: Stop-signal reaction time task acquisition in male 40,XY (n=11) and 39,XY*O (n=16) mice 
 
  1. Single nose-poking 2. Double nose-poking 3. Learning to stop 4. Training to BL 
 Group First session Last session First session Last session First session Last session First session Mean BL 
Number  
of sessions 
40,XY - 2.1±0.2 - 19.5±5.3 - 14.3±4.9 - 3.8±0.9 
39,XY*O - 5.6±0.9 - 15.3±2.9 - 7.2±0.8 - 11.6±2.5 
Number  
of trials 
40,XY 92.0±5.3 94.1±4.8 92.6±4.1 97.6±1.3 98.1±0.9 91.7±5.2 90.4±9.0 99.4±0.6 
39,XY*O 67.7±7.3 97.0±2.5 89.7±3.8 98.6±0.8 96.4±1.9 98.1±1.4 98.1±1.2 98.3±1.4 
Trials  
initiated (%) 
40,XY 71.7±7.0 87.4±3.2 71.0±8.4 53.9±6.0 62.0±7.6 66.6±6.0 57.1±7.3 74.1±3.5 
39,XY*O 60.8±9.5 89.5±1.9 71.8±4.9 79.9±4.3 81.1±5.1 83.3±3.7 76.0±6.4 80.8±3.5 
Initiation 
latency (s) 
40,XY 6.2±1.3 2.9±0.2 3.8±0.2 3.2±0.3 3.4±0.2 3.2±0.3 3.1±0.4 3.1±0.3 
39,XY*O 3.5±0.5 2.9±0.3 3.0±0.2 3.2±0.1 2.9±0.2 2.9±0.2 2.9±0.3 2.9±0.2 
Initiation stimulus 
duration (s) 
40,XY 10 10 10 10 10 10 10 10 
39,XY*O 10 10 10 10 10 10 10 10 
Latency to collect 
reward (s) 
40,XY 6.2±1.5 4.2±1.2 3.8±0.9 2.6±0.6 2.3±0.5 2.2±0.6 2.4±0.8 1.8±0.3 
39,XY*O 6.5±1.9 4.0±1.7 2.6±0.5 2.2±0.5 1.9±0.4 2.7±0.6 2.3±0.4 1.9±0.4 
Correct go  
trials (%) 
40,XY - - 82.6±5.3 80.9±3.8 83.0±5.2 86.6±4.3 82.3±8.6 87.0±2.6 
39,XY*O - - 82.8±4.7 77.3±2.6 78.5±4.9 81.6±2.9 78.5±6.4 83.1±2.4 
Correct go 
reaction time (ms) 
40,XY - - 2179.5±807.4 691.3±38.1 780.9±54.6 712.3±29.8 701.7±25.3 690.8±29.6 
39,XY*O - - 3272.3±909.0 715.8±24.8 813.3±36.0 724.5±29.2 732.4±35.1 735.2±25.6 
Go Stimulus 
duration (s) 
40,XY - - 30 2.1±0.3 1.6±0.2 1.05±0.3 1.1±0.1 1.0±0.1 
39,XY*O - - 30 1.9±0.1 1.3±0.2 0.9±0.0 0.9±0.0 0.9±0.0 
Correct stop  
trials (%) 
40,XY - - - - 96.0±2.1 84.1±5.2 76.7±9.4 84.8±2.8 
39,XY*O - - - - 99.1±0.6 90.3±3.4 84.0±6.8 91.5±2.9 
Stop incorrect 
reaction time (ms) 
40,XY - - - - 616.7±151.4 600.4±91.5 627.1±68.9 601.3±27.6 
39,XY*O 
- - - - 585.0±45.0 598.3±33.6 411.5±90.3 370.6±98.6 
Stop-signal  
position (%) 
40,XY - - - - 0 0 0 0 
39,XY*O - - - - 0 0 0 0 
Stop signal 
limited hold (s) 
40,XY - - - - 0.35±0.0 0.64±0.06 0.70±0.04 0.70±0.04 
39,XY*O - - - - 0.35±0.0 0.67±0.04 0.79±0.03 0.76±0.03 
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Table S3: Comparison of stop-signal reaction time task behaviour by 39,XY*O mice derived from 40,In(X)Paf/X (n=4) and 39,XPafO (n=12) mothers 
 
39,XY*O mice were bred from two genetically distinct mutant mothers (39,XPafO or 40,In(X)Paf/X). There was no obvious difference between mice from the 
different mothers in terms of acquisition of the SSRTT, with all mice reaching baseline criteria in ~40 sessions: 35.75±0.75 sessions for 40,In(X)Paf/X derived 
subjects and 40.33.±0.34 for 39,XPafO derived subjects (t14=-1.01, p=0.34).  There were also no group differences in baseline performance (0% stop-signal 
position), or in behavior during sessions in which the stop-signal was presented at 50% through the go response. 
 
Stop-signal 
position  
Maternal 
karyotype  
Correct stop 
trials (%)  SSRT (ms) 
Correct go 
trials (%) 
Correct go 
reaction time (ms) 
Trials 
initiated (%) 
Latency to 
initiate a trial (s) 
Latency to collect 
reinforcer (s) 
0% 
40,In(X)Paf/X 87.9±4.2 n/a 87.1±2.3 672.0±35.7 91.6±1.8 2.6±0.5 1.3±0.1 
39,XPafO 89.5±2.2 n/a 87.3±1.7 677.1±39.2 86.3±3.9 2.6±0.3 1.8±0.3 
t-test t14=-0.36, p=0.75  
t14=0.03,  
p=0.98 
t14=-0.10,  
p=0.93 
t14=-0.36, 
p=0.75 
t14=-0.01,  
p=0.99 
t14=-1.71,  
p=0.12 
         
50% 
40,In(X)Paf/X 67.7±8.3 274.5±35.7 84.1±1.8 679.9±39.9 87.5±3.3 2.9±0.86 1.4±0.1 
39,XPafO 75.5±4.7 210.7±20.7 86.7±2.2 684.3±42.0 85.2±3.2 2.7±0.19 1.8±0.2 
t-test t14=-0.83, p=0.45 
t14=1.55,  
p=0.18 
t14=-0.85, 
p=0.41 
t14=-0.08,  
p=0.94 
t14=0.51, 
p=0.62 
t14=0.28,  
p=0.83 
t14=-1.52,  
p=0.15 
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Table S4: Comparison of stop-signal reaction time task behaviour between singly (n=12) and group-housed (n=4) 39,XY*O mice 
 
Some 39,XY*O mice were housed singly for welfare reasons given their tendency to fight; the other 39,XY*O mice remained group-housed (i.e. two or more 
animals per home cage). Housing conditions did not influence the number of sessions taken by the mice to reach baseline criteria during task acquisition (group 
housed mice: 40.5±3.6 sessions and singly housed mice=35.3±8.8 sessions, t14=0.55, p=0.61), or performance at baseline and when the stop-signal was 
presented at 50% through the go response.  
 
Stop signal 
position  
Housing 
condition  
Correct stop 
trials (%)  SSRT (ms) 
Correct go 
trials (%) 
Correct go 
reaction time (ms) 
Trials 
initiated (%) 
Latency to 
initiate (s) 
Latency to collect 
reinforcer (s) 
0% 
Group  88.3±3.4 n/a 88.2±1.3 753.6±41.0 89.4±4.8 2.8±0.5 1.8±0.4 
Single 89.4±2.3 n/a 86.9±1.8 649.9±35.5 86.9±3.4 2.6±0.3 1.8±0.4 
t-test t14=0.22,  p=0.83  
t14=-0.63, 
p=0.54 
t14=-1.91,  
p=0.09 
t14=-0.41, 
p=0.70 
t14=-0.31, 
p=0.77 
t14=-0.25,  
p=0.81 
         
50% 
Group  62.3±8.2 259.8±25.4 84.0±3.5 767.8±62.1 87.5±4.2 3.1±0.8 1.9±0.3 
Single 77.3±4.3 215.6±23.1 86.7±2.0 655.0±35.7 85.1±3.1 2.7±0.2 1.8±0.3 
t-test t14=1.65,  p=0.16 
t14=-1.29, 
p=0.23 
t14=0.67,  
p=0.53 
t14=-1.58,  
p=0.17 
t14=-0.41, 
p=0.70 
t14=-0.47, 
p=0.66 
t14=-0.77,  
p=0.47 
 
 
